CAPOX
Checked 2026-09-09
Adjuvant stage III colon (3 or 6 months), rectal total neoadjuvant therapy, metastatic first line
Also called XELOX.
One cycle
every 21 days × 4 · about 12 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Oxaliplatin Third-generation platinum (DACH-platinum) | 130 mg/m² | IV | D1 | |
Capecitabine | 1,000 mg/m² twice daily | Oral | D1-14 |
Cycles
4 (3 months) or 8 (6 months)
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- Capecitabine dose is often started at 850 mg/m² in older patients or with renal impairment; check creatinine clearance.
- Hand-foot syndrome and diarrhoea drive dose holds; warfarin interaction is a boxed warning.
Used in
Source
NCCN Colon Cancer; IDEA collaboration, NEJM 2018
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
mFOLFOX6
Adjuvant stage III colon (6 months) or metastatic colorectal and upper GI first line
every 14 days × 12
FOLFIRI
Metastatic colorectal first or second line (with bevacizumab, aflibercept, ramucirumab or an anti-EGFR antibody)
every 14 days
FLOT
Resectable gastric or gastro-oesophageal junction adenocarcinoma, cT2 or higher or node-positive
every 14 days × 4
CROSS chemoradiation
Resectable oesophageal or junctional cancer (T1N1 or T2-3N0-1), before surgery
weekly × 5
Nivolumab + FOLFOX or CAPOX
Unresectable or metastatic HER2-negative gastric, junctional or oesophageal adenocarcinoma, first line (benefit concentrated in PD-L1 CPS 5 or above)
every 14 days
Pembrolizumab + cisplatin + fluorouracil
Advanced oesophageal or Siewert type 1 junctional cancer, first line
every 21 days
Trifluridine/tipiracil + bevacizumab
Refractory metastatic colorectal cancer after two lines
every 28 days
Pembrolizumab monotherapy
Adjuvant melanoma stage IIB-IV (1 year); PD-L1 TPS 50% or above NSCLC; MSI-high tumours; recurrent head and neck (CPS 1 or above)
every 21 days